GlassScriptPhysician profile
Daniela M Weiss
NPI 1770011603
$1,963.88
in general payments reported to CMS, 2019-2025
37 companies · $456 in 2025
The $456 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.41 · 2021: $164 · 2022: $452 · 2023: $375 · 2024: $489 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,219 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,219.47 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $411.00 | 2022-2025 | |
| Astellas Pharma US INC | $122.90 | 2025 | Padcev |
| Takeda Pharmaceuticals U.S.A., INC. | $114.18 | 2022 | |
| Jazz Pharmaceuticals INC. | $106.70 | 2021-2025 | |
| Eisai INC. | $87.94 | 2023-2025 | |
| Lilly USA, LLC | $78.71 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Celgene Corporation | $64.64 | 2019-2025 | Opdivo, Pomalyst |
| Merck Sharp & Dohme LLC | $59.59 | 2022-2024 | Keytruda |
| Gilead Sciences, INC. | $59.03 | 2021-2024 | |
| Glaxosmithkline, LLC. | $57.10 | 2022-2025 | Ojjaara |
| Aveo Pharmaceuticals, INC. | $56.57 | 2023 | Fotivda |
| Genzyme Corporation | $56.01 | 2022 | |
| Amgen INC. | $55.80 | 2022-2023 | Blincyto, Kyprolis |
| Pfizer INC. | $51.86 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $49.43 | 2022-2023 | Tagrisso, Lynparza |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $46.27 | 2022-2023 | Darzalex, Tecvayli, Erleada |
| Incyte Corporation | $43.14 | 2021-2025 | Monjuvi |
| Puma Biotechnology, INC. | $42.09 | 2025 | |
| Coherus Oncology, INC. | $39.90 | 2021 | |
| Foundation Medicine, INC. | $29.09 | 2022-2023 | |
| Genentech USA, INC. | $27.22 | 2025 | Venclexta |
| Regeneron Healthcare Solutions, INC. | $27.11 | 2025 | Libtayo |
| Karyopharm Therapeutics INC. | $24.12 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $23.32 | 2022 | |
| Daiichi Sankyo INC. | $22.64 | 2021 | |
| Beigene USA, INC. | $22.12 | 2023 | Brukinsa |
| Spectrum Pharmaceuticals INC. | $19.22 | 2023 | Rolvedon |
| Pharmacyclics LLC, An Abbvie Company | $18.96 | 2023 | Imbruvica |
| Rigel Pharmaceuticals, INC. | $18.56 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $18.51 | 2021 | |
| G1 Therapeutics, INC. | $18.37 | 2023 | Cosela |
| Pharmacosmos Therapeutics INC. | $17.30 | 2022 | |
| Taiho Oncology, INC. | $17.25 | 2024 | |
| Seagen INC. | $16.07 | 2023 | Tukysa |
| Emmaus Medical, INC. | $14.83 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.48 | 2019 | |
| Deciphera Pharmaceuticals INC. | $12.85 | 2023 | Qinlock |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.